Opportunities and obstacles for deep learning in biology and medicine
- PMID: 29618526
- PMCID: PMC5938574
- DOI: 10.1098/rsif.2017.0387
Opportunities and obstacles for deep learning in biology and medicine
Abstract
Deep learning describes a class of machine learning algorithms that are capable of combining raw inputs into layers of intermediate features. These algorithms have recently shown impressive results across a variety of domains. Biology and medicine are data-rich disciplines, but the data are complex and often ill-understood. Hence, deep learning techniques may be particularly well suited to solve problems of these fields. We examine applications of deep learning to a variety of biomedical problems-patient classification, fundamental biological processes and treatment of patients-and discuss whether deep learning will be able to transform these tasks or if the biomedical sphere poses unique challenges. Following from an extensive literature review, we find that deep learning has yet to revolutionize biomedicine or definitively resolve any of the most pressing challenges in the field, but promising advances have been made on the prior state of the art. Even though improvements over previous baselines have been modest in general, the recent progress indicates that deep learning methods will provide valuable means for speeding up or aiding human investigation. Though progress has been made linking a specific neural network's prediction to input features, understanding how users should interpret these models to make testable hypotheses about the system under study remains an open challenge. Furthermore, the limited amount of labelled data for training presents problems in some domains, as do legal and privacy constraints on work with sensitive health records. Nonetheless, we foresee deep learning enabling changes at both bench and bedside with the potential to transform several areas of biology and medicine.
Keywords: deep learning; genomics; machine learning; precision medicine.
© 2018 The Authors.
Conflict of interest statement
A.K. is on the Advisory Board of Deep Genomics Inc. E.F. is a full-time employee of GlaxoSmithKline. The remaining authors have no competing interests to declare.
Figures
References
Publication types
MeSH terms
Grants and funding
- U54 AI117924/AI/NIAID NIH HHS/United States
- UL1 TR001409/TR/NCATS NIH HHS/United States
- T32 GM007753/GM/NIGMS NIH HHS/United States
- R01 GM089652/GM/NIGMS NIH HHS/United States
- R01 AI116794/AI/NIAID NIH HHS/United States
- DP2 GM123485/GM/NIGMS NIH HHS/United States
- R01 LM012222/LM/NLM NIH HHS/United States
- R01 GM089753/GM/NIGMS NIH HHS/United States
- R01 LM012482/LM/NLM NIH HHS/United States
- R21 CA220398/CA/NCI NIH HHS/United States
- P30 CA051008/CA/NCI NIH HHS/United States
- P30 ES013508/ES/NIEHS NIH HHS/United States
- R35 GM122547/GM/NIGMS NIH HHS/United States
- T32 HG000046/HG/NHGRI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources